Award
National Cancer Institute 1R21CA317339-01
Photoacoustic molecular imaging for planning of neoadjuvant antibody-drug-conjugate treatment of triple negative breast cancer
Recipient
University of TX MD Anderson Cancer Center
Award Amount
$421,685.00
Ceiling
$421,685.00
Awarded
July 20, 2026
Identifier
1R21CA317339-01
This NIH-funded project aims to develop and validate a novel molecular photoacoustic imaging technique to improve treatment planning and monitoring for triple negative breast cancer patients undergoing antibody-drug-conjugate therapy.
Description
Develop molecular photoacoustic imaging using Trop-2-targeted contrast agents loaded with indocyanine green dye to non-invasively assess Trop-2 expression in triple negative breast cancer, predict and monitor response to sacituzumab govitecan therapy, and guide personalized treatment planning.